Authors' recommendations: Type 1 diabetes happens when the cells that make insulin in the pancreas, the islets, are destroyed. Islet cell transplantation involves extracting islet cells from the pancreas of a deceased donor and implanting them in the liver of someone with type 1 diabetes. This minor procedure is usually done twice for each transplant patient, and can be performed with minimal risk using a needle under local anaesthetic. Islet cell transplantation is suitable for patients with diabetes that is very hard to control. Once the islet cells are transplanted into the patient, proteins released by the patient's liver can cause the immune system to attack them and prevent them from working. Reparixin is a new drug that is given in a drip (directly into a vein). Some studies have suggested that reparixin may be able to prevent the islet cells from being damaged and therefore helping them to work better. If reparixin is licenced for use in the UK, it could be a new treatment option for patients with type 1 diabetes who have undergone islet cell transplantation.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/reparixin-for-prevention-of-delayed-graft-function-in-pancreatic-islet-transplantation-for-type-1-diabetes-mellitus/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)